A61K 49/128
Comprising multiple complex or complex-forming groups, being either part of the linear
Official title: {comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone}
A61K49/128 (Comprising multiple complex or complex-forming groups, being either part of the linear) appears on 85 US grants and 65 published applications in this corpus.
Search patents in A61K- Granted patents
- 85
- Published applications
- 65
- Assignees
- 77
- Inventors
- 258
- Latest grant
- 27 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 4 | 0 |
| 1993 | 3 | 0 |
| 1994 | 6 | 0 |
| 1995 | 6 | 0 |
| 1996 | 4 | 0 |
| 1997 | 8 | 0 |
| 1998 | 5 | 0 |
| 1999 | 5 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 2 | 1 |
| 2003 | 2 | 4 |
| 2004 | 2 | 2 |
| 2005 | 2 | 1 |
| 2006 | 1 | 4 |
| 2007 | 0 | 2 |
| 2008 | 0 | 2 |
| 2009 | 1 | 2 |
| 2010 | 3 | 2 |
| 2011 | 1 | 3 |
| 2012 | 0 | 6 |
| 2013 | 0 | 3 |
| 2014 | 2 | 4 |
| 2015 | 4 | 2 |
| 2016 | 1 | 2 |
| 2017 | 5 | 2 |
| 2018 | 2 | 4 |
| 2019 | 3 | 1 |
| 2020 | 1 | 3 |
| 2021 | 1 | 3 |
| 2022 | 2 | 1 |
| 2023 | 0 | 4 |
| 2024 | 2 | 3 |
| 2025 | 0 | 3 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compounds for use as iron(III) MRI contrast agents27 Jan 2026US 12,534,487 B2The Research Foundation for The State University of New York
- Compositions and methods for targeting cells10 Dec 2024US 12,161,663 B2Children's Medical Center Corporation
- Nanovectors and uses2 Jan 2024US 11,857,604 B2Nh Theraguix
- Polyrotaxanes bearing mixed cyclodextrin species and uses thereof6 Sep 2022US 11,434,330 B2Purdue Research Foundation
- Compounds for use as iron(III) MRI contrast agents1 Mar 2022US 11,261,208 B2The Research Foundation for The State University of New York
- Polymer contrast agent12 Feb 2026US 2026/0041776 A1Kowa Company, Ltd.
- Single-polymer particles, active molecular complex, method for producing single-polymer particles, method for measuring tumor size, method for measuring fine structure within tumor, method for imaging biological tissue, drug delivery system, and contrast agent kit23 Oct 2025US 2025/0325714 A1National Institutes for Quantum Science and Technology
- Nanostructure excreted in urine through kidney without being phagocytosed and/or metabolized by macrophage after in vivo injection11 Sep 2025US 2025/0281651 A1Inventera Inc.
- Compositions and methods for targeting cells13 Feb 2025US 2025/0049839 A1Children's Medical Center Corporation
- Nanostructure excreted in urine through kidney without being phagocytosed and/or metabolized by macrophage after in vivo injection28 Nov 2024US 2024/0390528 A1Inventera Inc.
Most cited
By later US patents
- Tumoricidal methotrexate-antibody conjugate378US 4,699,784 ACenter for Molecular Medicine and Immunology · 1987
- Diagnostic and therapeutic antibody conjugates285US 5,057,313 ACenter for Molecular Medicine and Immunology · 1991
- Percutaneous lymphography using particulate fluorocarbon emulsions165US 5,114,703 AAlliance Pharmaceutical Corp. · 1992
- Polychelating agents for image and spectral enhancement (and spectral shift)138US 5,155,215 AAccess Pharmaceuticals, Inc. · 1992
- Mixture of a positive and negative contrast agent for magnetic resonance imaging92US 5,128,121 ANYCOMED GmbH · 1992